Atlantic Equities upgrades Bristol-Myers Squbb (BMY) to "Neutral" from "Underweight" and sets a price target of $32.50 after the FDA approved the company's Eliquis anti-clotting drug last week. BMY is +2% at $32.55 premarket.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs